Structure of EGFR_D770_N771insNPG/V948R in complex with covalent inhibitor Osimertinib.

Experimental Data Snapshot

  • Resolution: 3.10 Å
  • R-Value Free: 0.305 
  • R-Value Work: 0.238 
  • R-Value Observed: 0.241 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.1 of the entry. See complete history


Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer.

Gonzalvez, F.Vincent, S.Baker, T.E.Gould, A.E.Li, S.Wardwell, S.D.Nadworny, S.Ning, Y.Zhang, S.Huang, W.S.Hu, Y.Li, F.Greenfield, M.T.Zech, S.G.Das, B.Narasimhan, N.I.Clackson, T.Dalgarno, D.Shakespeare, W.C.Fitzgerald, M.Chouitar, J.Griffin, R.J.Liu, S.Wong, K.K.Zhu, X.Rivera, V.M.

(2021) Cancer Discov 11: 1672-1687

  • DOI: https://doi.org/10.1158/2159-8290.CD-20-1683
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 

    Most EGFR exon 20 insertion ( EGFR ex20ins) driver mutations in non-small cell lung cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To address the limitations of existing therapies targeting EGFR -mutated NSCLC, mobocertinib (TAK-788), a novel irreversible EGFR TKI, was specifically designed to potently inhibit oncogenic variants containing activating EGFR ex20ins mutations with selectivity over wild-type EGFR. The in vitro and in vivo activity of mobocertinib was evaluated in engineered and patient-derived models harboring diverse EGFR ex20ins mutations. Mobocertinib inhibited viability of various EGFRex20ins-driven cell lines more potently than approved EGFR TKIs and demonstrated in vivo antitumor efficacy in patient-derived xenografts and murine orthotopic models. These findings support the ongoing clinical development of mobocertinib for the treatment of EGFR ex20ins-mutated NSCLC. SIGNIFICANCE: No oral EGFR-targeted therapies are approved for EGFR exon 20 insertion ( EGFR ex20ins) mutation-driven NSCLC. Mobocertinib is a novel small-molecule EGFR inhibitor specifically designed to target EGFRex20ins mutants. Preclinical data reported here support the clinical development of mobocertinib in patients with NSCLC with EGFR exon 20 insertion mutations. See related commentary by Pacheco, p. 1617 . This article is highlighted in the In This Issue feature, p. 1601 .

  • Organizational Affiliation

    ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Epidermal growth factor receptor
A, B, C, D
331Homo sapiensMutation(s): 1 
UniProt & NIH Common Fund Data Resources
Find proteins for P00533 (Homo sapiens)
Explore P00533 
Go to UniProtKB:  P00533
GTEx:  ENSG00000146648 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP00533
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 3 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Q6K (Subject of Investigation/LOI)
Query on Q6K

Download Ideal Coordinates CCD File 
E [auth A],
I [auth B],
M [auth C],
O [auth D]
C28 H35 N7 O2
Query on CIT

Download Ideal Coordinates CCD File 
C6 H8 O7
Query on EDO

Download Ideal Coordinates CCD File 
F [auth A]
G [auth B]
H [auth B]
J [auth B]
L [auth B]
F [auth A],
G [auth B],
H [auth B],
J [auth B],
L [auth B],
N [auth C]
C2 H6 O2
Experimental Data & Validation

Experimental Data

  • Resolution: 3.10 Å
  • R-Value Free: 0.305 
  • R-Value Work: 0.238 
  • R-Value Observed: 0.241 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 60.659α = 90
b = 132.1β = 91.4
c = 85.805γ = 90
Software Package:
Software NamePurpose
Aimlessdata scaling
PDB_EXTRACTdata extraction
DENZOdata reduction

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2021-09-22
    Type: Initial release
  • Version 1.1: 2023-10-18
    Changes: Data collection, Refinement description